MannKind Corporation (MNKD) Actualités

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

MannKind Expands Executive Leadership Team

Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025...

Form 8-K - Current report

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY...

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m...

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total...